← Human Trials & Peer-Reviewed Studies
Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial
Plain-language guide to PMID 26816605 (2016): open-label randomized controlled trial study of Insulin (regular human) and Insulin Aspart.
Key Facts
- PMID
- 26816605
- Journal
- Journal of diabetes investigation
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Yang W et al. (15 authors)
- DOI
- 10.1111/jdi.12364
- Registered trial
- NCT01618214
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin (regular human) and Insulin Aspart, published as a randomized controlled trial.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
In this 20-week, randomized, open-label, two-group parallel, multicenter trial, Chinese patients with type 2 diabetes inadequately controlled by premixed/self-mixed human insulin were randomized 1:1 to subject-driven or investigator-driven titration of BIAsp 30 BID, in combination with metformin and/or α-glucosidase inhibitors.
How the Study Was Run
The researchers set it up as a randomized, open-label, multicenter and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Insulin (regular human) and who got the comparison, which limits bias.
Nothing was hidden in this open-label Insulin (regular human) study: the participants and staff both knew the treatment.
More than one site took part, so the participants came from several places.
The Insulin (regular human) group and the comparison group ran side by side rather than switching.
What Was Measured
The subject headings attached to it are Asian People, Biphasic Insulins, Blood Glucose, China, Diabetes Mellitus, Type 2, Hypoglycemic Agents and Insulin Aspart.
Author keywords: Biphasic insulin aspart, Titration and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Insulin (regular human) and Insulin Aspart.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2016 (Journal of diabetes investigation), a journal based in Japan.
More context: the Insulin (regular human) compound page and the Insulin Aspart compound page.
Our Notes on the Compounds
Insulin (regular human): The 51-amino-acid pancreatic hormone that lowers blood glucose; this page covers regular (short-acting) insulin studied in human trials.
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
- Insulin (regular human) in the library
- Insulin Aspart in the library
- NPH Insulin (isophane) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.